Older adult APOE4 mice exhibit modest immunometabolic adaptation following microglial APOE2 replacement

Classified as probably not a substantial claim.

E2 expression decreases microgliosis compared to E3 and E4.

“decrease microgliosis”

• cites Murphy et al., 2025 sourceCould not verify

  The Results section on APOE2-expressing microglia reports a proliferation-associated gene module upregulated in APOE2 compared with APOE3 and APOE4, while the Discussion reports enhanced phagocytic activity. Neither passage measures microgliosis or says that APOE2 decreases it; searches for microgliosis and reduced microglial proliferation or number did not establish the claim. (LLM, conf=0.76)

  Experimental — accuracy not yet measured
• cites Nolt et al., 2025 sourcePartly supported

  The Results section on short remyelination reports lower IBA1+ microglial reactivity in mice with microglial E2 expression than in E4 controls, specifically in the corpus callosum after remyelination. It does not report an E2-versus-E3 comparison; the Discussion instead describes another study finding less microgliosis in E4 mice than in E3 or E2 mice following demyelination. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites Wang et al., 2022 sourceDisputed

  The Results section, “Microgliosis is dramatically increased in apoE2-TR mice,” reports the opposite: after cuprizone-induced demyelination, apoE2 mice had a larger increase in Iba1+ microglia than apoE4 mice, and higher Iba1 protein levels than both apoE3 and apoE4 mice. (LLM, conf=0.95)

  Checked by a reasoning model — may be wrong.

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim.

E2 expression decreases lipid accumulation compared to E3 and E4.

“decrease lipid accumulation”

• cites Murphy et al., 2025 sourceCould not verify

  The Results report that TSPAN13, a gene associated with lipid accumulation, is upregulated in APOE4 microglia; the Discussion suggests lipid dysregulation in APOE4 microglia. Neither passage reports lipid accumulation in APOE2 microglia compared with both APOE3 and APOE4. Searches for lipid accumulation and lipid droplets did not establish the claimed comparison. (LLM, conf=0.74)

  Experimental — accuracy not yet measured
• cites Nolt et al., 2025 sourcePartly supported

  The Results section, “Microglial APOE genotype modulates ApoE protein expression and lipid droplet distribution” (page unavailable), reports less astrocytic Plin2, a lipid-droplet marker, after remyelination in mice with microglial E2 replacement than in E4 controls. It found no significant difference in microglial Plin2 and did not test an E3 group, so it does not establish a general decrease in lipid accumulation compared with both E3 and E4. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites Wang et al., 2022 sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

APOE exists as three polymorphic alleles (APOE2, APOE3, APOE4) which encode three protein isoforms (apoE2, apoE3, and apoE4) distinguished by single amino acid substitutions at positions 112 and 158.

“APOE exists as three polymorphic alleles (APOE2, APOE3, APOE4) which encode three protein isoforms (apoE2, apoE3, and apoE4) distinguished by single amino acid substitutions at positions 112 and 158”

• cites Holtzman et al., 2012 sourceNot checked — no full text of the source
• cites Strittmatter et al., 1993 sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

Comparable findings have been reported following intraperitoneal LPS injection.

“and comparable findings have been reported following intraperitoneal LPS injection”

• cites Gale et al., 2014 sourceSupported

May combine two claims.

Metabolites that were lower in 4s2M (riboflavin, benzaldehyde, 1-aminocyclopropane-1-carboxylic acid) are not primary intermediates of central carbon metabolism and changes in their abundance may reflect shifts in cofactor handling or dietary metabolite uptake rather than broad changes in core metabolic pathways.

“Metabolites that were lower in 4s2M - riboflavin, benzaldehyde, and 1-aminocyclopropane-1-carboxylic acid – are not primary intermediates of central carbon metabolism and changes in their abundance may reflect shifts in cofactor handling or dietary metabolite uptake rather than broad changes in core metabolic pathways”

• cites Colombo et al., 1996 sourceNot checked — no full text of the source
• cites Kaya et al., 2023 sourceCould not verify

  Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured
• cites Wang et al., 2024 sourcePartly supported

  Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured

May combine two claims.

Increases in 3- and 4-hydroxyphenylacetic acid in 4s2M are consistent with alterations in aromatic amino acid-related metabolic flux; such metabolites can arise from tyrosine and monoamine pathways and may reflect systemic metabolic influences rather than direct energetic pathway remodeling.

“In contrast, increases in 3- and 4-hydroxyphenylacetic acid in 4s2M are consistent with alterations in aromatic amino acid–related metabolic flux; such metabolites can arise from tyrosine and monoamine pathways and may reflect systemic metabolic influences rather than direct energetic pathway remodeling”

• cites Borkowski et al., 2025 sourceCould not verify

  Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured
• cites Farup et al., 2023 sourceCould not verify

  Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured
• cites Jung et al., 2025 sourceCould not verify

  Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured

May combine two claims.

APOE genotype influences the inflammatory response, with E4 expression linked to significantly higher cytokine levels in both humans and mice compared to E3 or E2.

“In addition to metabolic dysregulation, APOE genotype also influences the inflammatory response, with E4 expression linked to significantly higher cytokine levels in both humans and mice compared to E3 or E2”

• cites Friday et al., 2025 sourcePartly supported

  The Results report higher cytokine secretion by E4 than E3 mouse microglia at baseline and under some treatments. The Discussion also cites studies showing exaggerated inflammatory responses in E4 mice and humans, but it does not establish significantly higher cytokine levels in humans or compare E4 with E2. It notes that E3 microglia had a stronger response to LPS, so the direction depends on the condition. (LLM, conf=0.89)

  Experimental — accuracy not yet measured
• cites Gale et al., 2014 sourcePartly supported

  The Results report higher cytokine responses in APOε3/APOε4 humans than APOε3/APOε3 humans after specified immune challenges, and higher plasma TNFα and G-CSF in LPS-challenged APOE4 mice than APOE3 mice. The study does not establish higher cytokine levels relative to APOE2 in either species; it also reports that some cytokine responses were similar between the E4 and E3 groups. (LLM, conf=0.90)

  Experimental — accuracy not yet measured
• cites Lynch et al., 2003 sourcePartly supported

  The Abstract and the section 'Effect of apoE Isoform on Inflammatory Response' report significantly higher TNFα and IL-6 levels in APOE4 mice than in APOE3 mice after LPS injection. The study did not compare cytokine levels with APOE2, and the Discussion describes the human evidence as preliminary rather than establishing significantly higher cytokine levels in humans. (LLM, conf=0.90)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim. May combine two claims.

Prior work shows that E4 impairs microglial metabolism/immune reactivity and can exaggerate cytokine reactivity to LPS.

“Prior work shows that E4 impairs microglial metabolism/immune reactivity and can exaggerate cytokine reactivity to LPS”

• cites Budny et al., 2025 sourceCould not verify

  The APOE section (page unavailable) says that APOE is involved in immune response and is produced to some extent by microglia, but does not describe E4 impairing microglial metabolism or immune reactivity. Searches for microglia, LPS, lipopolysaccharide, and cytokine reactivity found no passage in our copy reporting an exaggerated cytokine response to LPS. (LLM, conf=0.76)

  Experimental — accuracy not yet measured
• cites Gale et al., 2014 sourcePartly supported

  The Results section reports higher TNFα after LPS challenge in human APOε4 carriers and APOE4-targeted mice, supporting exaggerated cytokine reactivity to LPS. The paper’s reported experiments concern blood responses and systemic inflammation; our copy does not establish that E4 impairs microglial metabolism or microglial immune reactivity. Page numbers are unavailable in the indexed copy. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites Gao et al., 2023 sourcePartly supported

  In the Alzheimer’s disease section (page unavailable), Fig. 2 describes altered metabolism in APOE4-bearing microglia, and the text reports slower migration toward Aβ and less Aβ uptake with APOE4 than with APOE3. Those findings support altered metabolism and aspects of microglial function, but the passages do not link APOE4 to exaggerated cytokine reactivity after LPS stimulation. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Microglial replacement or reprogramming may represent a therapeutic strategy for neurodegenerative and neuroinflammatory disease.

“Several studies have demonstrated that microglial replacement or reprogramming may represent a therapeutic strategy for neurodegenerative and neuroinflammatory disease.”

• cites Chadarevian et al., 2024 sourcePartly supported

  The Discussion reports that transplanting healthy or CRISPR-corrected microglia prevented or reversed several pathologies in a mouse model of ALSP. The paper proposes replacement as a possible therapy for ALSP and perhaps other microglia-associated neurological disorders, but the cited passages do not establish therapeutic reprogramming or the broader claim across neurodegenerative and neuroinflammatory diseases. (LLM, conf=0.84)

  Experimental — accuracy not yet measured
• cites Han et al., 2020 sourcePartly supported

  The Introduction sections on microglial replacement report preclinical benefits and propose replacement as a potential treatment for CSF1R-related leukoencephalopathy. They also describe possible effects on neuroinflammation. The passages do not establish microglial reprogramming as a strategy or demonstrate therapeutic benefit across neurodegenerative and neuroinflammatory diseases generally; the paper presents clinical use as a possibility rather than a demonstrated result. Page numbers are unavailable in our copy. (LLM, conf=0.82)

  Experimental — accuracy not yet measured
• cites Kiani Shabestari et al., 2022 sourcePartly supported

  The Results (page unavailable) show that transplanted microglia engrafted in Alzheimer’s disease mice and reversed several disease-associated pathologies, supporting the potential of microglial replacement in that model. The paper does not establish reprogramming as a therapeutic strategy or test replacement across neurodegenerative and neuroinflammatory diseases more broadly. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim. May combine two claims.

Previous studies investigating the role of microglial E4 in amyloid and tau models have found that microglial E4 suppresses complement and lysosomal pathways, impairs lipid metabolism, and blunts glial responses to plaques, while its deletion restores a neuroprotective phenotype relative to E3.

“Previous studies investigating the role of microglial E4 in amyloid and tau models have found that microglial E4 suppresses complement and lysosomal pathways, impairs lipid metabolism, and blunts glial responses to plaques, while its deletion restores a neuroprotective phenotype relative to E3”

• cites Liu et al., 2023aNot matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites Yin et al., 2023 sourcePartly supported

  Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured

May combine two claims.

The 4s2M mice express APOE4 in all cell types except microglia, which selectively transition to APOE2 expression upon tamoxifen injection.

“We generated APOE4s2flox/flox xTmem119-CreERT2 APOE switch mice (4s2M) that would express APOE4 in all cell types except microglia, which would selectively transition to APOE2 expression upon tamoxifen injection”

• cites Golden et al., 2025 sourcePartly supported

  The ‘APOE switch’ mice section describes a tamoxifen-inducible APOE4-to-APOE2 switch, supporting the underlying switching mechanism. But the source describes global switching with ROSA26-CreERT1 and astrocyte-selective switching with Aldh1l1-CreERT2; its Methods > Animals section does not identify 4s2M or a Tmem119-CreERT2 microglia-selective cross. It therefore does not establish the claimed microglia-specific expression pattern. (LLM, conf=0.85)

  Experimental — accuracy not yet measured
• cites Nolt et al., 2025 sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

Intravenous LPS administration results in elevated proinflammatory cytokines in E4 mice compared to E3 mice within three hours of injection.

“Similarly, intravenous LPS administration results in elevated proinflammatory cytokines in E4 mice compared to E3 mice within three hours of injection”

• cites Lynch et al., 2003 sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

These findings align with studies showing that E2 supports efficient lipid turnover, mitochondrial function, and resilience to inflammatory stress.

“These findings align with studies showing that E2 supports efficient lipid turnover, mitochondrial function, and resilience to inflammatory stress”

• cites Gao et al., 2023 sourceCould not verify

  The Alzheimer’s disease treatment section discusses mitochondrial metabolism and reduced neuroinflammation after sodium rutin treatment, not E2. Searches for E2, estradiol, estrogen, and lipid turnover found no passage linking E2 to the three claimed effects in our copy; page numbers were unavailable. (LLM, conf=0.76)

  Experimental — accuracy not yet measured
• cites Lauro & Limatola, 2020 sourceCould not verify

  The ‘Warburg Effect’ and ‘Microglia Metabolic Remodeling as Therapeutic Approach’ sections discuss links between mitochondrial function and microglial inflammatory responses, but do not say that E2 supports those functions. Searches for E2, estradiol, and lipid metabolism found no passage addressing E2’s effects on lipid turnover, mitochondrial function, or resilience to inflammatory stress. The indexed copy provides no page numbers for these sections. (LLM, conf=0.72)

  Experimental — accuracy not yet measured
• cites Ning et al., 2024 sourcePartly supported

  The Results (APOE2 pathway-level alterations; page unavailable) report enhanced triglyceride catabolism and changes in cholesterol metabolism in APOE2 carriers, while the Abstract Results report improved mitochondrial function and reduced reactive oxygen species in Aβ-stimulated cells. These findings support the lipid-metabolism and mitochondrial portions, though they do not establish efficient lipid turnover broadly. The Results also report altered immune-related pathways, but do not show resilience to inflammatory stress. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Microglia from LPS-treated mice exhibit distinct APOE genotype-dependent metabolic profiles.

“Moreover, microglia from LPS-treated mice exhibit distinct APOE genotype–dependent metabolic profiles”

• cites Lee et al., 2023 sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

Pharmacological targeting of metabolic pathways to modulate microglial activation has shown promise in preclinical studies.

“Similarly, pharmacological targeting of metabolic pathways to modulate microglial activation has shown promise in preclinical studies (Amo-Aparicio et al., 2024; Gao et al., 2023; Lepiarz-Raba et al., 2023).”

• cites Amo-Aparicio et al., 2024 sourcePartly supported

  The Alzheimer’s disease section (page not provided) reports that 2-DG blocked microglial cytokine release and that IFNγ restored metabolic signaling and some microglial functions in 5XFAD mice. It calls restoration of microglial metabolism a potential therapeutic target, but does not clearly establish that pharmacological targeting of metabolic pathways has shown therapeutic promise across preclinical studies. (LLM, conf=0.80)

  Experimental — accuracy not yet measured
• cites Gao et al., 2023 sourceSupported
• cites Lepiarz-Raba et al., 2023 sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

In total, 188 pathways were significantly enriched (FDR < 0.01) in the GSEA.

“In total, 188 pathways were significantly enriched (FDR < 0.01).”

May combine two claims.

A microglia-specific transition from E4 to E2 does not impact weight or survival following a chronic Western diet.

“A microglia-specific transition from E4 to E2 does not impact weight or survival following a chronic Western diet”

May combine two claims.

Riboflavin, benzaldehyde, and 1-aminocyclopropane-1-carboxylic acid were reduced in 4s2M relative to 4s2, whereas 3- and 4-hydroxyphenylacetic acid were increased.

“Specifically, riboflavin, benzaldehyde, and 1-aminocyclopropane-1-carboxylic acid were reduced in 4s2M relative to 4s2, whereas 3- and 4-hydroxyphenylacetic acid were increased (Fig. 3B).”

May combine two claims.

Both 4s2 and 4s2M groups showed increases in body weight over the WD, with no statistically significant difference in percent weight change between groups.

“Both 4s2 and 4s2M groups showed increases in body weight over the duration of the WD, with no statistically significant difference in percent weight change between groups”

May combine two claims.

Whole brain metabolomic analysis revealed limited separation between 4s2 and 4s2M following WD, with PLS-DA showing minimal separation between groups.

“Whole brain metabolomic analysis (101 metabolites identified) revealed limited separation between 4s2 and 4s2M following WD, with partial least squares-discriminant analysis (PLS-DA) showing minimal separation between groups (Fig. 3A).”

May combine two claims.

Differential expression analysis revealed an upregulation of Gstm1, Pcdhgc4, and Isoc2a and a downregulation of Kcng3, Utp20, Lcor, Zfp280b, Pura, Amer1, Ankhd1, and Tcerg1 in 4s2M compared to 4s2 mice following LPS.

“Differential expression analysis revealed an upregulation of Gstm1, Pcdhgc4, and Isoc2a and a downregulation of Kcng3, Utp20, Lcor, Zfp280b, Pura, Amer1, Ankhd1, and Tcerg1 in 4s2M compared to 4s2 mice following LPS (Fig. 4B).”

May combine two claims.

Specific lipid species differed between 4s2 and 4s2M, including increased abundance of CE(24:5), LPC(22:5), and SM(d18:2/18:1), and decreased abundance of DHA-containing plasmalogens PE(O-18:0/22:6) and PC(P-18:1/22:6) in 4s2M mice.

“Volcano plot analysis identified several lipid species that differed between 4s2 and 4s2M, including increased abundance of CE(24:5), LPC(22:5), and SM(d18:2/18:1), and decreased abundance of DHA-containing plasmalogens PE(O-18:0/22:6) and PC(P-18:1/22:6) in 4s2M mice (Fig. 3E).”

May combine two claims.

Heatmap analysis of the top 50 most differentially abundant lipids showed differences across several lipid species, including triacylglycerols, ceramides, and cholesterol esters, but did not reveal a consistent global pattern of lipid remodeling.

“Heatmap analysis of the top 50 most differentially abundant lipids showed differences across several lipid species, including triacylglycerols, ceramides, and cholesterol esters, but did not reveal a consistent global pattern of lipid remodeling (Fig. 3F).”

May combine two claims.

No statistically significant differences were detected in total or cell-specific apoE area, reactive astrocytes, myeloid cells/macrophages, or microglia between 4s2 and 4s2M following WD.

“Neither regional, nor whole hemisphere analyses detected statistically significant differences in total or cell-specific apoE area”

• Also stated in: § Microglial replacement with E2 decreases phago-lysosomal microglia following a Western diet challenge in older adult mice · plain

  “reactive astrocytes (GFAP; t=0.8223, df=12.40; p = 0.4265; mean difference = 0.4185 (95% CI: −0.6865 to 1.523))”

• Also stated in: § Microglial replacement with E2 decreases phago-lysosomal microglia following a Western diet challenge in older adult mice · plain

  “myeloid cells/macrophages (CD68; t=1.882, df=11.01; p = 0.0865; mean difference = −0.1011 (95% CI: −0.2192 to 0.01709)), or microglia (IBA1; t=1.077, df=10.18; p = 0.3063; mean difference = −0.6435 (95% CI: −1.971 to 0.6844))”

Probably not a substantial claim: may not pass S3 (load-bearing).

The E4 allele is associated with earlier age of onset of Alzheimer's disease compared to E3 and E2.

“the E4 allele is associated with increased risk, earlier age of onset, and greater severity of AD compared to the most commonly expressed E3 and the protective E2 allele”

• cites Blacker et al., 1997 sourceNot checked — no full text of the source
• cites Corder et al., 1994 sourceNot checked — no full text of the source
• cites Corder et al., 1993 sourceNot checked — no full text of the source

Classified as probably not a substantial claim.

The E4 allele is associated with greater severity of Alzheimer's disease compared to E3 and E2.

“the E4 allele is associated with increased risk, earlier age of onset, and greater severity of AD compared to the most commonly expressed E3 and the protective E2 allele”

• cites Blacker et al., 1997 sourceNot checked — no full text of the source
• cites Corder et al., 1994 sourceNot checked — no full text of the source
• cites Corder et al., 1993 sourceNot checked — no full text of the source

Classified as probably not a substantial claim.

The E4 allele is associated with increased risk of Alzheimer's disease compared to E3 and E2.

“the E4 allele is associated with increased risk, earlier age of onset, and greater severity of AD compared to the most commonly expressed E3 and the protective E2 allele”

• cites Blacker et al., 1997 sourceNot checked — no full text of the source
• cites Corder et al., 1994 sourceNot checked — no full text of the source
• cites Corder et al., 1993 sourceNot checked — no full text of the source

May combine two claims.

Although whole-brain transcriptomic differences were observed following LPS administration, these changes were not accompanied by statistically significant differences in whole-brain microglial marker expression, cytokine levels, or gliosis under the conditions tested and within the statistical power of the current study.

“Together, these findings indicate that although whole-brain transcriptomic differences were observed following LPS administration, these changes were not accompanied by statistically significant differences in whole-brain microglial marker expression, cytokine levels, or gliosis under the conditions tested and within the statistical power of the current study.”

• AssumptionThe authors state this as an assumption: All other non-microglia cells continue to express E4 in 4s2M mice.

Probably not a substantial claim: may not pass S3 (load-bearing).

Because colocalization measurements can be influenced by changes in microglial morphology, the observed reduction may also reflect alterations in microglial structure or intracellular distribution of CD68.

“Additionally, because colocalization measurements can be influenced by changes in microglial morphology, the observed reduction may also reflect alterations in microglial structure or intracellular distribution of CD68.”

May combine two claims.

Together, these findings indicate that microglial E2 expression is associated with selective cellular and transcriptional changes while E4 continues to be expressed by other cell types.

“Together, these findings indicate that microglial E2 expression is associated with selective cellular and transcriptional changes while E4 continues to be expressed by other cell types.”

• Also stated in: § Introduction · plain

  “Together, these findings identify cellular and transcriptional changes associated with microglial E2 expression while E4 remains expressed in other cell types”

Probably not a substantial claim: may not pass S3 (load-bearing).

Using older adult mice in both the WD and LPS paradigms may have exacerbated, blunted, or inhibited some of the study's characterizations.

“We utilized older adult mice in both the WD and LPS paradigms which may exacerbate, blunt, or inhibit some of our characterizations.”

May combine two claims.

Unchallenged baseline control groups of each genotype were not included, so the study could not formally assess genotype × treatment interactions or definitively distinguish treatment-induced effects from underlying genotype differences.

“Additionally, unchallenged baseline control groups of each genotype were not included; thus, we are unable to formally assess genotype × treatment interactions or definitively distinguish treatment-induced effects from underlying genotype differences.”

Probably not a substantial claim: may not pass S3 (load-bearing).

All samples within each assay were processed in a single experimental run where applicable.

“all samples within each assay were processed in a single experimental run where applicable”

May combine two claims.

Microglial E2 replacement was associated with a transcriptional profile enriched for metabolic and immune-related pathways following LPS administration but did not detect statistically significant differences in DAM-associated genes, cytokine levels, or glial cell reactivity measures in older adult mice at 24 hours post-LPS administration.

“We found that microglial E2 replacement was associated with a transcriptional profile enriched for metabolic and immune-related pathways following LPS administration but did not detect statistically significant differences in DAM-associated genes, cytokine levels, or glial cell reactivity measures in older adult mice at 24 hours post-LPS administration.”

• AssumptionThe authors state this as an assumption: All other non-microglia cells continue to express E4 in 4s2M mice.

Classified as probably not a substantial claim.

Cre-negative littermates (4s2) were employed as controls across all experiments.

“Cre-negative littermates (4s2) were employed as controls across all experiments.”

May combine two claims.

Replacing microglial E4 with E2 was associated with reduced phago-lysosomal microglia and alterations in the lipid profile, while no statistically significant differences in other glial cell or metabolic measures were detected in the brains of older adult mice fed a WD.

“Overall, we found that replacing microglial E4 with E2 was associated with reduced phago-lysosomal microglia and alterations in the lipid profile, while we did not detect statistically significant differences in other glial cell or metabolic measures in the brains of older adult mice fed a WD.”

• AssumptionThe authors state this as an assumption: All other non-microglia cells continue to express E4 in 4s2M mice.

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Several animals died prior to endpoint collection, resulting in final cohort sizes of 4s2: N = 7 female, N = 3 male; 4s2M: N = 7 female, N = 4 male.

“Several animals died prior to endpoint collection, resulting in final cohort sizes of 4s2: N = 7 female, N = 3 male; 4s2M: N = 7 female, N = 4 male.”

May combine two claims.

Microglial E2 expression is associated with reduced phago-lysosomal microglial markers and reduced apoE localization within phagolysosomal microglia in older adult mice fed a WD.

“These findings indicate that microglial E2 expression is associated with reduced phago-lysosomal microglial markers and reduced apoE localization within phagolysosomal microglia in older adult mice fed a WD.”

• Also stated in: § Discussion · plain

  “Microglial E2 expression was associated with reduced phago-lysosomal microglia and decreased apoE localization within phago-lysosomal microglia in older adult mice fed a Western diet.”

• AssumptionThe authors state this as an assumption: All other non-microglia cells continue to express E4 in 4s2M mice.

May combine two claims.

In 4s2M mice, genes related to mitochondrial metabolism, protein synthesis, and antigen presentation were enriched, suggesting differences in metabolic and immune-related transcriptional programs associated with microglial E2 expression.

“In 4s2ᴹ mice, where microglia express E2 in an otherwise E4 background, genes related to mitochondrial metabolism, protein synthesis, and antigen presentation were enriched, suggesting differences in metabolic and immune-related transcriptional programs associated with microglial E2 expression.”

• AssumptionThe authors state this as an assumption: All other non-microglia cells continue to express E4 in 4s2M mice.

Probably not a substantial claim: may not pass S3 (load-bearing).

No covariates (e.g., sex or batch) were included in statistical models.

“No covariates (e.g., sex or batch) were included in statistical models.”

May combine two claims.

Microglial targeting of APOE expression may have limited impact on immunometabolic regulation and could be less effective than other microglia-directed approaches (such as microglial replacement) for mitigating E4-driven dysfunction.

“However, the limited effects we see at the whole-brain level in both our WD and LPS studies suggests that microglial targeting of APOE expression may have limited impact on immunometabolic regulation and could be less effective than other microglia-directed approaches (such as microglial replacement) for mitigating E4-driven dysfunction.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Sex inclusion differed across experimental paradigms due to constraints in animal availability and cohort design, limiting the ability to systematically assess sex as a biological variable across all datasets.

“Sex inclusion differed across experimental paradigms due to constraints in animal availability and cohort design at the time of study implementation, which limited the ability to systematically assess sex as a biological variable across all datasets”

May combine two claims.

Microglial E2 expression is associated with changes in select whole-brain lipid species under WD conditions, while broad lipidomic differences between groups were not detected.

“Together, these findings indicate that microglial E2 expression is associated with changes in select whole-brain lipid species under WD conditions, while broad lipidomic differences between groups were not detected.”

• AssumptionThe authors state this as an assumption: All other non-microglia cells continue to express E4 in 4s2M mice.

May combine two claims.

While microglial E2 expression is associated with differences in specific lipid species, it does not appear to drive broad changes in the overall brain lipid profile following a late-life WD.

“These results indicate that while microglial E2 expression is associated with differences in specific lipid species, it does not appear to drive broad changes in the overall brain lipid profile following a late-life WD.”

• AssumptionThe authors state this as an assumption: All other non-microglia cells continue to express E4 in 4s2M mice.

Probably not a substantial claim: may not pass S3 (load-bearing).

No batch effects were present in the immunofluorescence datasets.

“No batch effects were present in the immunofluorescence datasets”

May combine two claims.

Microglial E2 replacement does not globally alter apoE abundance or its association with IBA1+ microglia, but instead is associated with redistribution of apoE away from phago-lysosomal microglia.

“suggesting that microglial E2 replacement does not globally alter apoE abundance or its association with IBA1+ microglia, but instead is associated with redistribution of apoE away from phago-lysosomal microglia.”

• AssumptionThe authors state this as an assumption: All other non-microglia cells continue to express E4 in 4s2M mice.

May combine two claims.

Analyses were performed on whole-brain tissue, which reflects mixed cell populations and may reduce the ability to specifically attribute observed transcriptional and metabolic changes to microglial E2 effects.

“Also, our analyses were performed on whole-brain tissue, which reflects mixed cell populations and may reduce the ability to specifically attribute observed transcriptional and metabolic changes to microglial E2 effects.”

Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based). May combine two claims.

Variability in LPS responsiveness across studies (including ours) may reflect differences in administration route (i.p. vs. i.c.v. vs. i.v.), post-injection time points (6 vs 24 vs. 72 hours), mouse age, or the specific microglial APOE isoform expressed (E2 vs. E3 vs. E4).

“It is important to note that the variability in LPS responsiveness across studies (including ours) may reflect differences in administration route (i.p. vs. i.c.v. vs. i.v.), post-injection time points (6 vs 24 vs. 72 hours), mouse age, or the specific microglial APOE isoform expressed (E2 vs. E3 vs. E4).”

May combine two claims.

Sensitivity analyses (α = 0.05, 80% power) indicated that the Western diet and LPS studies were only powered to detect very large effects (Cohen's d = 1.16-1.30) but underpowered to detect moderate or smaller, potentially biologically relevant differences, limiting interpretation of non-significant findings.

“Sensitivity analyses (α = 0.05, 80% power) indicated that the Western diet and LPS studies were only powered to detect very large effects (Cohen’s d = 1.16–1.30) but underpowered to detect moderate or smaller, potentially biologically relevant differences, limiting our interpretation of non-significant findings.”